GIST pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
26 of 32 arms with a reported figure. Choose arms to narrow the chart.
Imatinib 400 mg. best overall response (complete 5.3% plus partial 46.1%): 51.4%, combined analysis, Sum of label complete response 43 (5.3%) and partial response 377 (46.1%)
Imatinib 400 mg. objective response rate (SWOG): 68.5%, up to 36 months
Imatinib 600 mg. objective response rate (SWOG): 67.6%, up to 36 months
Sunitinib 50 mg. objective response rate (partial responses): 6.8%, interim analysis
Ripretinib 150 mg. objective response rate (BICR): 9%, primary analysis
Ripretinib 150 mg. objective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03
Ripretinib 50 mg. objective response rate, KIT exon 11 ITT: 14.6%, primary analysis
Avapritinib 300 or 400 mg. overall response rate (independent review): 84%, median follow up 10.6 months
Avapritinib 300 or 400 mg. overall response rate (independent review): 89%, median follow up 10.6 months
Avapritinib 300 mg. objective response rate: 17.1%, primary analysis
Avapritinib 160 mg. objective response rate: 7.2%, primary analysis
Bezuclastinib + Sunitinib 600 mg + 37.5 mg. objective response rate (BICR): 46%, data cutoff 09.30.2025
Bezuclastinib + Sunitinib 37.5 mg. objective response rate (BICR): 26%, data cutoff 09.30.2025
Velzatinib (IDRX-42, GSK6042981) 300 mg. objective response rate: 35%, cutoff 12.15.2025
Velzatinib (IDRX-42, GSK6042981) 300 mg. unconfirmed objective response rate: 61%, median follow up 6.4 months
Olverembatinib (HQP1351) 30 to 50 mg. partial response as best response: 23.1%, cutoff 11.13.2025
NB003 not stated in source. objective response rate: 28.5%, data as of March 2025
NB003 not stated in source. objective response rate: 46.7%, data as of March 2025
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.